Multiple sclerosis (MS) is the commonest non‐traumatic disabling disease to affect young
adults. The incidence of MS is increasing worldwide, together with the socioeconomic …

An individualized innovative disease management is of great importance for people with
multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional …

ABSTRACT The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating and categorizing …

The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple
sclerosis (MS) and primary progressive MS has led to a conceptual shift in the …

Abstract Narcolepsy type 1 (NT1) is a chronic sleep disorder resulting from the loss of a
small population of hypothalamic neurons that produce wake-promoting hypocretin (HCRT; …

Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

The modern era of multiple sclerosis (MS) treatment began 25 years ago, with the approval
of IFNβ and glatiramer acetate for the treatment of relapsing–remitting MS. Ten years later …

Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …